"10.1371_journal.pone.0078656","plos one","2013-10-22T00:00:00Z","Silvia La Monica; Cristina Caffarra; Francesca Saccani; Elena Galvani; Maricla Galetti; Claudia Fumarola; Mara Bonelli; Andrea Cavazzoni; Daniele Cretella; Rita Sirangelo; Rita Gatti; Marcello Tiseo; Andrea Ardizzoni; Elisa Giovannetti; Pier Giorgio Petronini; Roberta R Alfieri","Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy; Department Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; Italian Workers Compensation Authority (INAIL) Research Center at the University of Parma, Italy; Department of Biotechnology, Biomedical and Translational Sciences, University of Parma, Parma, Italy; Division of Medical Oncology, University Hospital of Parma, Parma, Italy","Conceived and designed the experiments: SL RRA PGP. Performed the experiments: SL CC FS E. Galvani MG CF MB RS. Analyzed the data: E. Giovannetti AA RRA. Contributed reagents/materials/analysis tools: RG DC AC. Wrote the manuscript: RRA SL E. Giovannetti. Critically revision of the manuscript: PGP AA MT.","This work was supported by AstraZeneca. The Gefitinib used in this study is marketed by AstraZeneca and was provided by them. NVP-BEZ235 was provided by Novartis Institutes for BioMedical Research. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","10","Silvia La Monica","SLM",16,TRUE,3,4,1,3,TRUE,FALSE,TRUE,4,"5;6;7;10",TRUE
